Yunkang Group Limited (HK:2325)
:2325
Top Page
Yunkang Group Limited
(2325)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$0.84
▼(-14.85% Downside)
Action:ReiteratedDate:10/23/25
The overall stock score of 46 reflects significant financial challenges, including declining revenues and negative profitability. Technical analysis indicates bearish momentum, and valuation metrics are concerning with a negative P/E ratio. The company's modest dividend yield provides limited support.
Positive Factors
Manageable Leverage
A moderate debt-to-equity ratio provides financial flexibility over the medium term, lowering default risk and giving management room to allocate cash toward operations, R&D, or restructuring. This durable capital structure helps sustain operations through cyclical revenue pressure and supports strategic investments.
Negative Factors
Declining Revenues & Negative Margins
Sustained revenue decline and contracting gross and net margins undermine long-term profitability and operational scalability. Negative EBIT/EBITDA margins signal structural cost or pricing issues that require strategic fixes; without revenue stabilization, margins may remain pressured and cash generation could deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
A moderate debt-to-equity ratio provides financial flexibility over the medium term, lowering default risk and giving management room to allocate cash toward operations, R&D, or restructuring. This durable capital structure helps sustain operations through cyclical revenue pressure and supports strategic investments.
Read all positive factors
Yunkang Group Limited (2325) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$515.64M
Dividend Yield2.15%
Average Volume (3M)1.61M
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue Growth-18.98%
EPS Growth-164.82%
CountryHK
Employees1,249
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.11
Shares Outstanding621,250,500
10 Day Avg. Volume4,171,850
30 Day Avg. Volume1,613,200
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.52
Price to Sales (P/S)7.26
P/FCF Ratio22.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$884.18M
Yunkang Group Limited Business Overview & Revenue Model
Company Description
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the e...
How the Company Makes Money
Yunkang Group Limited generates revenue through multiple streams, primarily from the sale of its traditional Chinese medicine products and health supplements. The company capitalizes on the increasing consumer interest in natural and holistic heal...
Yunkang Group Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 645.16M | 711.88M | 891.50M | 3.76B | 1.70B | 1.20B |
| Gross Profit | 189.24M | 211.07M | 325.79M | 1.47B | 1.07B | 726.08M |
| EBITDA | -597.39M | -668.52M | 25.07M | 569.53M | 496.15M | 366.88M |
| Net Income | -720.89M | -791.68M | -102.26M | 377.31M | 380.93M | 255.33M |
Balance Sheet | ||||||
| Total Assets | 3.06B | 3.23B | 4.53B | 5.51B | 3.00B | 2.32B |
| Cash, Cash Equivalents and Short-Term Investments | 1.69B | 1.73B | 1.87B | 1.43B | 800.70M | 485.83M |
| Total Debt | 1.02B | 1.07B | 1.39B | 786.12M | 362.02M | 497.23M |
| Total Liabilities | 1.96B | 2.08B | 2.41B | 2.66B | 1.23B | 1.06B |
| Stockholders Equity | 1.10B | 1.14B | 2.33B | 2.84B | 1.45B | 1.24B |
Cash Flow | ||||||
| Free Cash Flow | 161.48M | 228.38M | 271.63M | -239.05M | 141.06M | -86.66M |
| Operating Cash Flow | 171.25M | 258.84M | 333.84M | 130.33M | 413.26M | 221.08M |
| Investing Cash Flow | 63.78M | 354.02M | -153.94M | -1.25B | 310.72M | -191.09M |
| Financing Cash Flow | -202.32M | -535.63M | 276.48M | 1.10B | -215.32M | 260.99M |
Yunkang Group Limited Technical Analysis
Neutral
0.99
Price Trends
0.83
Positive
0.92
Negative
1.73
Negative
Market Momentum
>-0.01
Positive
49.84
Neutral
33.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2325, the sentiment is Neutral. The current price of 0.99 is above the 20-day moving average (MA) of 0.86, above the 50-day MA of 0.83, and below the 200-day MA of 1.73, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 33.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2325.
Yunkang Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.61B | 20.66 | 5.64% | 1.20% | 2.05% | -285.88% | |
46 Neutral | HK$515.64M | -19.30 | -34.90% | 2.15% | -18.98% | -164.82% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― | |
41 Neutral | HK$1.08B | -176.64 | -13.92% | ― | -32.17% | -1.20% |
* Healthcare Sector Average
HK:2325
Yunkang Group Limited
0.83
-2.41
-74.38%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
10.91
-0.09
-0.82%
HK:3309
C-MER Eye Care Holdings Limited
1.31
-0.09
-6.43%
HK:6667
Mega Genomics Limited
7.38
0.18
2.50%
Yunkang Group Limited Corporate Events
Yunkang Group Signs New Three-Year Connected Lease with Controlling Shareholder
Dec 31, 2025
Yunkang Group Limited has entered into a new three-year property lease agreement under which its subsidiary Guangzhou Daan will lease around 10,468 sq m of premises in Guangzhou’s Science City from controlling shareholder Da An Gene, along w...
Yunkang Group Announces Change in Board Lot Size
Dec 10, 2025
Yunkang Group Limited has announced a change in the board lot size for its shares traded on The Stock Exchange of Hong Kong Limited. Effective January 2, 2026, the board lot size will increase from 500 shares to 3,000 shares. This change is intend...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.